What are the considerations for the pharmacotherapeutic management of acute promyelocytic leukemia in children?

References

• Gurnari C, Voso MT, Girardi K, et al. Acute promyelocytic leukemia in children: a model of precision medicine and chemotherapy-free therapy. Int J Mol Sci. 2021 Jan 11;22(2):2.
   Web of Science ®Google Scholar
• Mazzarella L, Botteri E, Matthews A, et al. Obesity is a risk factor for acute promyelocytic leukemia: evidence from population and cross-sectional studies and correlation with FLT3 mutations and polyunsaturated fatty acid metabolism. Haematologica. 2020 Jun;105(6):1559–1566.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017 Jan 26;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Fenaux P, Tallman MS, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019 Apr 11;133(15):1630–1643.
   PubMed Web of Science ®Google Scholar
• Falanga A, Russo L, Tartari CJ. Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia. Mediterr J Hematol Infect Dis. 2011;3(1):e2011068.
   PubMedGoogle Scholar
• Gurnari C, Breccia M, Di Giuliano F, et al. Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinico-biological parameters. Br J Haematol. 2020 Aug 10;193(1):129–132.
   PubMed Web of Science ®Google Scholar
• Rajpurkar M, Alonzo TA, Wang Y-C, et al. Risk markers for significant bleeding and thrombosis in pediatric acute promyelocytic leukemia; report from the Children’s Oncology Group Study AAML0631. J Pediatr Hematol Oncol. 2019;41(1):1.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang L, Zhang R, et al. Long-term follow-up of children with acute promyelocytic leukemia treated with Beijing Children’s Hospital APL 2005 protocol (BCH-APL 2005). Pediatr Hematol Oncol. 2019 Oct 03;36(7):399–409.
   PubMed Web of Science ®Google Scholar
• de Azevedo AC, Matsuda E, Cervellini JY, et al. Early mortality in children and adolescents with acute promyelocytic leukemia: experience of the Boldrini Children’s Center. J Pediatr Hematol Oncol. 2020;42(7):7.
   Web of Science ®Google Scholar
• Naymagon L, Moshier E, Tremblay D, et al. Predictors of early hemorrhage in acute promyelocytic leukemia. Leuk Lymphoma. 2019 Oct;60(10):2394–2403.
   PubMed Web of Science ®Google Scholar
• Testi AM, Pession A, Diverio D, et al. Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL. Blood. 2018 Jul 26;132(4):405–412.
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Avvisati G, Vignetti M, et al., Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 369(2): 111–121. 2013.
   PubMed Web of Science ®Google Scholar
• Cicconi L, Platzbecker U, Avvisati G, et al. Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. Leukemia. 2020 Mar;34(3):914–918.
   PubMed Web of Science ®Google Scholar
• Gurnari C, De Bellis E, Divona M, et al. When poisons cure: the case of arsenic in acute promyelocytic leukemia. Chemotherapy. 2019;64(5–6):238–247.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Gore SD. New strategies in acute promyelocytic leukemia: moving to an entirely oral, chemotherapy-free upfront management approach. Clin Cancer Res. 2014;20(19):4985–4993.
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Hasan SK. Understanding the molecular pathogenesis of acute promyelocytic leukemia. Best Pract Res Clin Haematol. 2014 Mar 01;27(1):3–9.
   PubMed Web of Science ®Google Scholar
• Zhang X-W, Yan X-J, Zhou Z-R, et al. Arsenic trioxide controls the fate of the PML-RARα oncoprotein by directly binding PML. Science (New York, N.Y.). 2010;328(5975):240–243.
   PubMed Web of Science ®Google Scholar
• Lallemand-Breitenbach V, Jeanne M, Benhenda S, et al. Arsenic degrades PML or PML–RARα through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol. 2008 May 01;10(5):547–555.
   PubMed Web of Science ®Google Scholar
• Cicconi L, Testi AM, Montesinos P, et al. Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants. Blood Cancer J. 2021 Oct 16;11(10):167.
   PubMed Web of Science ®Google Scholar
• Ciangola G, Gurnari C, Paterno G, et al. STAT5b-RARa-positive acute myeloid leukemia: diagnostic and therapeutic challenges of a rare AML subtype. Leuk Res. 2019 Mar;78:21–23.
   PubMed Web of Science ®Google Scholar
• Montesinos P, Bergua JM, Vellenga E, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood. 2009 Jan 22;113(4):775–783.
   PubMed Web of Science ®Google Scholar
• Stahl M, Tallman MS. Differentiation syndrome in acute promyelocytic leukaemia. Br J Haematol. 2019 Oct;187(2):157–162.
   PubMed Web of Science ®Google Scholar
• Anoop TM, Jain N, Nair SG, et al. All-trans-retinoic acid-induced pseudotumor cerebri in acute promyelocytic leukemia [Article]. J Neurosci Rural Pract. 2014;5(3):273–275.
   PubMedGoogle Scholar
• Montesinos P, Vellenga E, Holowiecka A, et al. Incidence, outcome and risk factors of pseudotumor cerebri after all- trans retinoic acid and anthracycline-based chemotherapy in patients with acute promyelocytic leukemia. Blood. 2008;112(11):2992.
   Web of Science ®Google Scholar
• Coombs CC, DeAngelis LM, Feusner JH, et al. Pseudotumor cerebri in acute promyelocytic leukemia patients on intergroup protocol 0129: clinical description and recommendations for new diagnostic criteria. Clin Lymphoma Myeloma Leuk. 2016 Mar;16(3):146–151.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Zhang L, Wu J, et al. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience. Eur J Haematol. 2013;91(6):483–489.
   PubMed Web of Science ®Google Scholar
• Creutzig U, Dworzak MN, Bochennek K, et al. First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid. Pediatr Blood Cancer. 2017 Aug;64(8):e26461.
   Web of Science ®Google Scholar
• Strocchio L, Gurnari C, Santoro N, et al. Arsenic trioxide and all-trans retinoic acid treatment for childhood acute promyelocytic leukaemia. Br J Haematol. 2019 Apr;185(2):360–363.
   PubMed Web of Science ®Google Scholar
• Garcia Spezza E, Brethon B, Petit A, et al. Tolerance to arsenic trioxide combined with all-trans-retinoic acid in children with acute promyelocytic leukaemia in France. Br J Haematol. 2020;188(1):170–173.
   PubMed Web of Science ®Google Scholar
• Li SY, Lu Y, Liu HC, et al. Arsenic trioxide and all-trans retinoic acid in the treatment of children with newly diagnosed acute promyelocytic leukemia. Leuk Lymphoma. 2021 May;62(5):1267–1270.
   PubMed Web of Science ®Google Scholar
• Zheng H, Jiang H, and Hu S, et al. Arsenic combined with all-trans retinoic acid for pediatric acute promyelocytic leukemia: report from the CCLG-APL2016 protocol study. J Clin Oncol. 2021 October 1;39(28):3161-3170. DOI: https://doi.org/10.1200/JCO.20.03096
   Google Scholar
• Cicconi L, Divona M, Ciardi C, et al. PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy. Leukemia. 2016 Oct;30(10):1987–1992.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Avvisati G, Cicconi L, et al. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol. 2017 Feb 20;35(6):605–612.
   PubMed Web of Science ®Google Scholar
• Breccia M, Loglisci G, Loglisci MG, et al. FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols: long-term follow-up analysis. Haematologica. 2013 Dec;98(12):e161–3.
   PubMed Web of Science ®Google Scholar
• Testi AM, Mohamed S, Diverio D, et al. Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients - a 25-year Italian experience. Br J Haematol. 2021 Jun;192(1):17.
   PubMedGoogle Scholar
• Abla O, Kutny MA, Testi AM, et al., Management of relapsed and refractory childhood acute promyelocytic leukaemia: recommendations from an international expert panel. Br J Haematol. 175(4): 588–601. 2016.
   PubMed Web of Science ®Google Scholar
• Pau M, Joaquín D-M, Guillermo D, et al. Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. Haematologica. 2009 Sep 01;94(9):1242–1249.
   PubMed Web of Science ®Google Scholar